Fasenra frees asthma patients from oral corticosteroids

29 October 2020
fasenra_big

Top-line results from the Phase IIIb PONENTE study show that 62% of people with severe asthma were able to stop using oral corticosteroids (OCS) when treated with Fasenra (benralizumab).

AstraZeneca (LSE: AZN) said the interleukin (IL)-5 receptor binding biologic eliminated the use of maintenance OCS use in people with a broad range of blood eosinophil counts.

The trial met both primary endpoints, with 81% of people achieving complete elimination or a reduction in daily use of OCS treatment to 5mg or less, when further reduction was not possible due to adrenal insufficiency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology